ALEXANDRIA, Va. – Findings from the phase III placebo-controlled SPARTAN trial suggest that apalutamide is an effective treatment for men with non-metastatic castration-resistant prostate cancer (nmCRPC) who are at high risk for developing metastatic disease, and for whom no approved treatments exist. Men who received apalutamide had a 72% lower risk of metastasis or death than those who received placebo.
ALEXANDRIA, Va. – A new analysis of the ongoing STAMPEDE clinical trial found that adding the chemotherapy drug docetaxel to hormone therapy for advanced prostate cancer improves quality of life and lowers the need for subsequent therapy. Docetaxel was also found to be cost-effective. These findings will be presented at the upcoming 2018 Genitourinary Cancers Symposium in San Francisco, California.
ALEXANDRIA, VA — A new and unique new way to treat cancer – CAR T-cell therapy – is poised to transform the outlook for children and adults with certain otherwise incurable cancers. The American Society of Clinical Oncology (ASCO) named this type of adoptive cell immunotherapy the Advance of the Year in its annual report. Released today in advance of World Cancer Day, Clinical Cancer Advances 2018 highlights the most impactful clinical cancer research and policy developments over the past year.
"Over the past few decades we’ve seen global cancer death rates drop thanks to dramatic improvements in diagnosis and treatment. But the unfortunate reality is that millions of patients worldwide are not yet reaping the benefits of the progress we’ve made because of inability to access care. All too often, where someone lives dictates their chances of surviving cancer."
ALEXANDRIA, Va. – Co-sponsors of the 2018 Cancer Survivorship Symposium announced today five abstracts that will be highlighted in the meeting’s official Press Program. Researchers will present the findings of these studies in an embargoed presscast for reporters, taking place Monday, February 12, 2018, from 12:00 noon – 1:30 p.m. ET.
The following studies will be featured during the presscast:
The American Society of Clinical Oncology (ASCO) congratulates Alex Azar for his confirmation as Secretary of the U.S. Department of Health and Human Services (HHS). As the head of HHS, Secretary Azar has an opportunity to help address critical issues facing the cancer care delivery system, including increasing access to high-quality care, addressing the high cost of care, and supporting the development and dissemination of innovative treatments
ALEXANDRIA, Va. — CancerLinQ LLC and the American College of Medical Genetics and Genomics (ACMG), the medical specialty society for clinical and laboratory genetics professionals, have entered into a programmatic collaboration. CancerLinQ®, the American Society of Clinical Oncology’s (ASCO) health information technology platform designed by oncologists for oncologists to leverage the power of big data to help improve the quality of care for patients with cancer, will benefit from the knowledge and expertise of ACMG leadership and members.
SAN FRANCISCO – Eight noteworthy studies exploring the implications of immuno-oncology for patient care will be presented at the 2018 ASCO-SITC Clinical Immuno-Oncology Symposium. The meeting will take place January 25-27 at the San Francisco Marriott Marquis in San Francisco, California. These notable abstracts discuss the efficacy of immunotherapy in rare cancers, biomarkers to predict which patients will benefit most, and managing the adverse effects of immune-based treatments.
ALEXANDRIA, Va. — A registry that tracks the quality of medical care provided to patients receiving cancer treatment launched this month as part of a collaboration between the American Society of Clinical Oncology (ASCO) and the American Society for Radiation Oncology (ASTRO). In addition to improving the quality of care for people living with cancer, the Quality Oncology Practice Initiative (QOPI®) Reporting Registry also makes it easier for medical and radiation oncologists to report quality-related performance metrics required by the federal government.
Alexandria, Va.—CancerLinQ LLC and the Association for Molecular Pathology (AMP), a global, molecular diagnostics professional society, have entered into a collaboration. AMP leadership and members will be applying the breadth of their knowledge to CancerLinQ®, the American Society of Clinical Oncology’s (ASCO) health information technology platform designed to leverage the power of big data to help conquer cancer.
ALEXANDRIA, Va. – A new study has found that a test that identifies circulating tumor cells (CTCs) present in the bloodstream can detect colorectal cancer at an early stage, with accuracy ranging from 84 to 88%. Most prior studies using CTCs have been able to detect late-stage colorectal cancer, and this study is one of the first clinical studies to show that CTCs can be useful for detecting early, more treatable stages of the cancer. These findings will be presented at the upcoming 2018 ASCO Gastrointestinal Cancers Symposium in San Francisco, California.
ALEXANDRIA, Va. – Co-sponsors of the 2018 Genitourinary Cancers Symposium announced today four abstracts to be highlighted in the meeting’s official Press Program. Researchers will present the findings of these studies in an embargoed presscast for reporters, taking place Monday, February 5, 2018, from 12:00 noon – 1:30 p.m. ET.
ALEXANDRIA, Va. — CancerLinQ LLC and the National Society of Genetic Counselors (NSGC), the professional society for genetic counselors, announced today that they have entered into a strategic alliance. With the collaboration, NSGC leaders and members will provide expertise to CancerLinQ®, the American Society of Clinical Oncology’s (ASCO) health information technology platform aimed at improving the quality of cancer care using real-world cancer data.
With the Tax Cuts and Jobs Act on the verge of being signed into law, the American Society of Clinical Oncology (ASCO) is concerned about across-the-board cuts to Medicare that the measure will trigger. We urge Congress to protect Medicare beneficiaries with cancer and other medical conditions by passing additional legislation to avoid cuts to the program.